CoChat

Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1

Open access
Palmerini, Emanuela, Agostinelli, Claudio, Picci, Piero, Pileri, Stefano, Marafioti, Teresa, Lollini, Pier-Luigi, Scotlandi, Katia, Longhi, Alessandra, Benassi, Maria Serena, Ferrari, Stefano · 2017 · Oncotarget
Cited by 65

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

// Emanuela Palmerini 1 , Claudio Agostinelli 2 , Piero Picci 1 , Stefano Pileri 3, 4 , Teresa Marafioti 5 , Pier-Luigi Lollini 6 , Katia Scotlandi 1 , Alessandra Longhi 1 , Maria Serena Benassi 1 and Stefano Ferrari 1 1 Chemotherapy Unit, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy 2 Haematopathology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy 3 Haematopathology Unit, European Institute of Oncology, Milan, Italy 4 Bologna University School of Medicine, Bologna, Italy 5 University College London Cancer Institute, London, United Kingdom 6 Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy Correspondence to: Emanuela Palmerini, email: emanuela.palmerini3@unibo.it Keywords: osteosarcoma; PD-1; PD-L1; CD8; tumor microenvironment Received: July 19, 2017 Accepted: November 15, 2017 Published: December 04, 2017 ABSTRACT Background: We hypothesized that immune-infiltrates were associated with superior survival, and examined a primary osteosarcoma tissue microarrays (TMAs) to test this hypothesis. Methods: 129 patients (pts) with localized osteosarcoma treated within protocol ISG-OS1 were included in the study. Clinical characteristics, expression of CD8, CD3, FOXP3, CD20, CD68/CD163 (tumor associated macrophage, TAM), Tia-1 (cytotoxic T cell), CD303 (plasmacytoid dendritic cells: pDC), Arginase-1 (myeloid derived suppressor cells: MDSC), PD-1 on immune-cells (IC), and PD-L1 on tumoral cells (TC) and IC were analysed and correlated with outcome. Results: Most of the cases presented tumor infiltrating lymphocytes (TILs) (CD3+ 90%; CD8+ 86%). Tia-1 was detected in 73% of the samples. PD-L1 expression was found in 14% patients in IC and 0% in TC; 22% showed PD-1 expression in IC. With a median follow-up of 8 years (range 1-13), the 5-year overall survival (5-year OS) was 74% (95% CI 64-85). Univariate analysis showed better 5-year OS for: a) pts with a good histologic response to neoadjuvant chemotherapy (p = 0.0001); b) pts with CD8/Tia1 tumoral infiltrates (p = 0.002); c) pts with normal alkaline phosphatas (sALP) (p = 0.04). After multivariate analysis, histologic response (p = 0.007) and CD8/Tia1 infiltration (p = 0.01) were independently correlated with survival. In the subset of pts with CD8+ infiltrate, worse (p 0.02) OS was observed for PD-L1(IC)+ cases. Conclusions: Our findings support the hypothesis that CD8/Tia1 infiltrate in tumor microenvironment at diagnosis confers superior survival for pts with localized osteosarcoma, while PD-L1 expression is associated with worse survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.22912

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 65

Metadata

Authors
Palmerini, E., Agostinelli, C., Picci, P., Pileri, S., Marafioti, T., Lollini, P.-L., Scotlandi, K., Longhi, A., Benassi, M. S., & Ferrari, S.
Venue
Oncotarget
Published
2017-12-04
Volume
8
Issue
67
Pages
111836-111846
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2774372124
Cited by
65
References
10
FWCI
5.26
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.